ORIC PHARMACEUTICALS INC (ORIC) Stock News

USA - Nasdaq - NASDAQ:ORIC - US68622P1093 - Common Stock

10.98 USD

+0.33 (+3.1%)

Last: 12/3/2025, 8:00:02 PM

10.98 USD

0 (0%)

After Hours: 12/3/2025, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ORIC Latest News, Press Relases and Analysis

All

Press Releases

12 hours ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025

12 hours ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025

3 days ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025

10 days ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

10 days ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

14 days ago - By: Benzinga - Mentions: BRKR NDAQ MMC AGIO ...

This Nasdaq Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

14 days ago - By: Benzinga - Mentions: BRKR AGIO GLOB BRBR ...

This Bellring Brands Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday

16 days ago - By: Zacks Investment Research

Oric Pharmaceuticals (ORIC) Upgraded to Buy: Here's What You Should Know

21 days ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates

21 days ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates

21 days ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety

a month ago - By: ORIC Pharmaceuticals

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: ORIC Pharmaceuticals

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor

a month ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor

a month ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

a month ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

a month ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors

a month ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors

3 months ago - By: ORIC Pharmaceuticals

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: ORIC Pharmaceuticals

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

3 months ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

4 months ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer

4 months ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer

4 months ago - By: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates

4 months ago - By: ORIC Pharmaceuticals

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: ORIC Pharmaceuticals

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: ORIC Pharmaceuticals

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: ORIC Pharmaceuticals

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Zacks Investment Research

All You Need to Know About Oric Pharmaceuticals (ORIC) Rating Upgrade to Buy

6 months ago - By: Yahoo Finance - Mentions: AMZN PLTR WMT COST ...

Palantir Stock vs. Amazon Stock: Wall Street Says Buy One and Sell the Other

6 months ago - By: ORIC Pharmaceuticals

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: ORIC Pharmaceuticals

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Zacks Investment Research

Wall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals (ORIC): Here's What You Should Know